本文へスキップします。

[All]hlink
H1

News Detail

お知らせ:表示

Notice regarding Acquisition of Dellegra® from Sanofi to LTL Pharma

INVESTMENT

2020/08/04

PDF
August 4, 2020
Unison Capital, Inc.




Notice regarding Acquisition of Dellegra® from Sanofi to LTL Pharma



 It is with great pleasure to announce that LTL Pharma Co., Ltd. (“LTL Pharma”), which is owned by Unison Capital Partners IV, LPS and Unison Capital Partners IV(F), L.P. (collectively, “Unison”), has entered into an asset purchase agreement with Sanofi under which Sanofi will transfer the ownership and rights associated with Dellegra® (Generic Name: combination tablet of Fexofenadine and Pseudophedrine) to LTL Pharma.

 Dellegra® has been manufactured and sold by Sanofi K.K. (“Sanofi”) since its authorization in 2012. In accordance with the asset purchase agreement regarding Dellegra®, Sanofi will transfer the marketing authorization (MA) and sales activities to LTL Pharma. This MA transfer is scheduled to be executed this year, and post-MA transfer completion, LTL Pharma will oversee manufacturing and sales of Dellegra®.

 Through LTL Pharma, Unison continues to seek opportunities to acquire LLPs from various pharmaceutical companies and expand a platform through which LLPs are stably supplied and distributed, which enables Unison/LTL Pharma to simultaneously contribute to two critical societal needs - the acceleration of new drug development by pharmaceutical companies and the long-term stable supply of LLPs.


Dellegra®
“Dellegra® combination tablet” is an oral drug combining “Allegra®” (Generic Name: Fexofenadine), which is a 2nd generation antihistamine, and Pseudophedrine, which is an alpha-adrenergic agonist along with the effect of shrinking blood vessels. One tablet of Dellegra® helps patients with allergic rhinitis and moderate or higher nasal congestion to ease three major symptoms of allergic rhinitis (sneeze, runny nose, and stuffy nose) all together. Authorized in December 25, 2012. Launched in February 28, 2013.


Contact
Please direct all inquiries concerning this matter to:
Public Relations
Tel: +81-3-3511-3900

view list